VALBIOTIS (EPA:ALVAL) | Finanzwire

Basculer en Français

9472	Companies
185369	Keywords
117719	Articles
99261	Press releases

Home
Companies
VALBIOTIS

BRIEF

published on 11/25/2025 at 14:05, 9 days 16 hours ago

Valbiotis: Monthly information on voting rights and shares

Share Capital Voting Rights Euronext Growth Regulation Valbiotis
BRIEF

published on 11/25/2025 at 14:05, 9 days 16 hours ago

Valbiotis: Information on Share Capital and Voting Rights

Share Capital Voting Rights Euronext Growth Valbiotis AMF Regulations
PRESS RELEASE

published on 11/17/2025 at 17:50, 17 days 12 hours ago

Correction of a release from 17.11.2025 17:40 CET/CEST - VALBIOTIS SA: Valbiotis announces a major strategic agreement in Asia
Valbiotis announces strategic agreement with Chinese group Aika to commercialize ValbiotisPRO® products in multiple Asian markets starting in 2026, leveraging CBEC model for rapid market entry

Valbiotis Commercialization Asia Strategic Agreement Aika
BRIEF

published on 11/17/2025 at 17:45, 17 days 12 hours ago

Valbiotis joins forces with Aika for a strategic partnership in Asia

E-commerce Valbiotis International Strategy Aika Asian Joint Venture
PRESS RELEASE

published on 11/17/2025 at 17:40, 17 days 12 hours ago

VALBIOTIS SA: Valbiotis announces a major strategic agreement in Asia
Valbiotis announces a major strategic agreement in Asia with Chinese group Aika for the commercialization of health products in key markets, starting with ValbiotisPRO® range as early as 2026

Joint Venture Valbiotis Asia Strategic Agreement Health Products
BRIEF

published on 10/13/2025 at 17:50, 1 month 22 days ago

VALBIOTIS SA: Information on shares and voting rights

Share Capital Voting Rights Euronext Growth Valbiotis Threshold Crossing
BRIEF

published on 10/13/2025 at 17:50, 1 month 22 days ago

VALBIOTIS SA: Monthly update on share capital

Share Capital Voting Rights Euronext Growth Regulation Valbiotis
BRIEF

published on 10/09/2025 at 17:50, 1 month 26 days ago

Valbiotis Publishes Interim Financial Results, Confirms Growth Path

Growth Strategy Financial Results Valbiotis Dietary Supplements Commercial Expansion
PRESS RELEASE

published on 10/09/2025 at 17:45, 1 month 26 days ago

VALBIOTIS SA: Valbiotis publishes its interim financial statements and confirms its roadmap
Valbiotis publishes its interim financial statements, confirms roadmap with successful commercialization, cash position of €13.2M, and growth drivers for 2026. Increased engagement with partners and all financial ambitions through 2030 affirmed

Cash Position Valbiotis Commercialization Interim Financial Statements Growth Drivers
PRESS RELEASE

published on 10/09/2025 at 17:45, 1 month 26 days ago

VALBIOTIS SA: Valbiotis publishes its interim financial statements and confirms its roadmap
Valbiotis publishes interim financial results with robust commercialization timeline, solid cash position and growth drivers activated, while confirming financial ambitions through 2030. International engagements with partners intensify

Financial Results Cash Position Valbiotis Growth Drivers Commercialization Timeline

Accesswire

Published on 12/05/2025 at 02:35, 3 hours 34 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 3 hours 39 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 5 hours 9 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 7 hours 4 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 7 hours 9 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 03:30, 2 hours 39 minutes ago

CGTN: What makes cooperation between China and France a two-way success
Published on 12/04/2025 at 23:50, 6 hours 18 minutes ago

EQS-Adhoc: Dexus Finance Pty Limited: Dexus prices A$500 million of subordinated notes
Published on 12/04/2025 at 20:25, 9 hours 44 minutes ago

Newmark Appoints Globally Recognized Real Estate Executive Peter Trollope to Lead Occupier Solutions
Published on 12/04/2025 at 20:15, 9 hours 54 minutes ago

Galimedix Therapeutics presents compelling Phase 1 study results showing excellent safety and pharmacokinetics with oral small molecule GAL-101 at CTAD 2025
Published on 12/04/2025 at 19:10, 10 hours 59 minutes ago

SCHOTT Pharma’s preliminary results for fiscal year 2025; outlook for FY 2026 and update of mid-term guidance

Les Echos

Published on 12/04/2025 at 18:00, 12 hours 9 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 12 hours 24 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 12 hours 25 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution
Published on 12/04/2025 at 07:01, 23 hours 8 minutes ago

bioMérieux launches leading endocrinology testing offer dedicated to enhancing equine health
Published on 12/03/2025 at 18:00, 1 day 12 hours ago

Declaration of voting rights at the end of November 2025

View all LES ECHOS COMFI WIRE